| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
5,780,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.3302 - $0.3302 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Phio Pharmaceuticals is developing therapeutics that use its INTASYL™ technology to target both tumor and immune cells by regulating genes to strengthen a patient's immune system while weakening tumor defense mechanisms. Co.'s INTASYL-based therapeutics are used to: strengthen immune cells, for example those administered as part of adoptive cell therapy (ACT), and directly modify cells in the tumor microenvironment to weaken a tumor's defense. Co.'s lead product candidate being developed by Co. in ACT is PH-762. Co.'s second product candidate in development for use in ACT is PH-894. Co.'s INTASYL compound PH-804 is also being developed for use in ACT.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
2,500 |
6,500 |
22,216 |
| Total Buy Value |
$0 |
$2,275 |
$14,195 |
$22,362 |
| Total People Bought |
0 |
1 |
2 |
2 |
| Total Buy Transactions |
0 |
1 |
4 |
12 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Cauwenbergh Geert |
President & CEO |
• • – |
2014-09-15 |
4 |
B |
$2.18 |
$21,849 |
D/D |
10,000 |
41,000 |
2.81 |
- |
|
| Advanced Rna Technologies, Llc |
No longer 10% owner |
– – – |
2014-07-31 |
4 |
B |
$2.48 |
$992 |
D/D |
400 |
1,221,723 |
2.36 |
- |
|
| Cauwenbergh Geert |
President & CEO |
• • – |
2014-07-15 |
4 |
B |
$2.50 |
$2,500 |
D/D |
1,000 |
31,000 |
2.73 |
- |
|
| Cauwenbergh Geert |
President & CEO |
• • – |
2014-07-09 |
4 |
B |
$2.57 |
$3,598 |
D/D |
1,400 |
30,000 |
2.73 |
- |
|
| Cauwenbergh Geert |
President & CEO |
• • – |
2014-07-02 |
4 |
B |
$2.85 |
$5,713 |
D/D |
2,000 |
28,600 |
2.81 |
- |
|
| Cauwenbergh Geert |
President & CEO |
• • – |
2014-06-25 |
4 |
B |
$3.01 |
$1,505 |
D/D |
500 |
26,600 |
2.73 |
- |
|
| Cauwenbergh Geert |
President & CEO |
• • – |
2014-06-19 |
4 |
B |
$2.96 |
$5,960 |
D/D |
2,000 |
26,100 |
2.81 |
- |
|
| Cauwenbergh Geert |
President & CEO |
• • – |
2014-06-09 |
4 |
B |
$3.05 |
$3,050 |
D/D |
1,000 |
24,100 |
2.73 |
- |
|
| Cauwenbergh Geert |
President & CEO |
• • – |
2014-06-04 |
4 |
B |
$2.91 |
$5,886 |
D/D |
2,000 |
23,100 |
2.81 |
- |
|
134 Records found
|
|
Page 6 of 6 |
|
|
